If earnings are driving the rally, then next week is going to be very telling. "I want to be careful of some stocks," Cramer said.» Read More
Public criticism of Goldman Sachs has come to China, where the investment bank has been lambasted in articles in state-controlled media, the FT reported.
Cramer offers six ways a healthy sense of doubt is benefiting stocks.
Volatile activity in the capital markets has caused mixed results with initial public offerings.
Already, 10 of the 34 IPOs priced this year have been VC-backed and almost a third of the 105 deals in the six-month backlog are backed by venture capital.
The chipmakers have been part of some of the best offerings this year. Now Cramer has his eye on another one.
Cramer teaches you how to dig down on companies that are coming public.
If a deal can’t pass Cramer’s test, then it’s not worth buying.
Cramer explains the little-known mechanics of these popular deals.
One important factor is behind a few key quarterly reports, Cramer says. Plus, get his calls on housing, IPOs and more.
This deal, the first of its kind since 2007, could be a great buy, Cramer says.
For the first time since October 2007, we’re seeing 6 IPOs in one week. What's the trade?
A company isn’t legit just because it’s publicly traded.
You thought the Dow’s new high for the year marked a peak? Think again, Cramer says.
Despite the weakness in IPO activity so far this year, David DiPietro, president of Signal Hill, expects at least 100 initial public offerings by the end of 2010.
The board of Russian aluminium company UC RUSAL has set a price range for its Hong Kong IPO valuing the company at between $16 billion and $22 billion, a paper reported.
This past year has been a lackluster one for public offerings, but David DiPietro, president of Signal Hill, predicts there will be an average of two to three IPOs per week in 2010.
Following a boom in Asian initial public offerings (IPO) this year, investors will be more discerning in 2010 as they scrutinize these offerings more closely, said Mark Konyn, CEO of RCM Asia Pacific.
A key hematology conference and earnings reports offer investors six stocks to watch.
Hint: Not in the most obvious locations, or on traditional items. Plus, an IPO recommendation.
Well, maybe. But here’s why Cramer likes it.